Trial Profile

An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gimeracil/oteracil/tegafur/folinic acid (Primary) ; Cisplatin; Folinic acid; Gimeracil/oteracil/tegafur; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Registrational; Therapeutic Use
Acronyms SOLAR
Sponsors Taiho Pharmaceutical

Most Recent Events

04 Aug 2020 Status changed from active, no longer recruiting to completed.
16 Jul 2020 Results published in the Lancet Oncology
16 Jul 2020 Primary endpoint (Overall survival) has been met as per results published in the THE LANCET ONCOLOGY

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com